MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (MIRA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MIRA · as of Sep 30, 2025
Ownership Breakdown
29
Institutional Holders
▲ 9 vs Q2
$1.89M
Total Inst. Value
▲ $682,348 vs Q2
42.02M
Shares Outstanding
freeFloat 63.93%
1.40M
13F Shares Held
▲ 395,085 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MIRA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CROSS STAFF INVESTMENTS INC pharmaceutical preparations | 359.4K | 2.12% | 2.12% | $488.79M | Oct 24, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 203.6K | 1.20% | 1.20% | $276.95M | Nov 7, 2025 | ▲ 85.8K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 136.4K | 80.32% | 80.32% | $185.56M | Nov 12, 2025 | ▲ 1.1K |
BLACKROCK, INC. pharmaceutical preparations | 109.8K | 64.62% | 64.62% | $149.29M | Nov 12, 2025 | NEW |
SUNCOAST EQUITY MANAGEMENT pharmaceutical preparations | 103.3K | 60.81% | 60.81% | $140.47M | Oct 21, 2025 | — held |
FIRST AMERICAN BANK pharmaceutical preparations | 50.0K | 29.44% | 29.44% | $68.00M | Oct 20, 2025 | ▲ 30.0K |
STATE STREET CORP pharmaceutical preparations | 49.1K | 28.91% | 28.91% | $66.78M | Nov 14, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 46.7K | 27.49% | 27.49% | $63.51M | Nov 13, 2025 | NEW |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 45.7K | 26.91% | 26.91% | $62.16M | Nov 14, 2025 | ▲ 25.8K |
J.W. COLE ADVISORS, INC. pharmaceutical preparations | 45.5K | 26.79% | 26.79% | $61.88M | Nov 5, 2025 | ▲ 4.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
9
Increased
+192.4K shares10
New Positions
first time holders1
Decreased
−284 shares1
Sold Out
fully exitedNet shares change (top 50)
+192.1K
+192.4K / −284
Net new holders
+17
10 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MIRA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Aminov Erez Chief Executive Officer | Mar 30, 2026 | Award | 83,500 | — | — | 83.5K | Form 4 ↗ |
Aminov Erez CEO and Chairman | Dec 17, 2025 | Award | 3,155,170 | $1.45 | $4.57M | 3.16M | Form 4 ↗ |
Shekhat Denil Nanji director | Oct 1, 2025 | Award | 22,378 | $1.35 | $30.2K | 22.4K | Form 4 ↗ |
Aminov Erez Chief Executive Officer | Oct 1, 2025 | Award | 2,685,456 | — | — | 3.53M | Form 4 ↗ |
Aminov Erez Chief Executive Officer | Sep 18, 2025 | Award | 150,000 | $1.38 | $207.0K | 150.0K | Form 4 ↗ |
Aminov Erez Chief Executive Officer | Aug 29, 2025 | Award | 62,500 | $1.37 | $85.6K | 844.7K | Form 4 ↗ |
Whalen Matthew Pratt director | Dec 9, 2024 | Award | 25,000 | $1.19 | $29.8K | 25.0K | Form 4 ↗ |
MacPherson Edward Clouston director | Dec 9, 2024 | Award | 25,000 | $1.19 | $29.8K | 25.0K | Form 4 ↗ |
Yanez Michelle Chief Financial Officer | Dec 9, 2024 | Award | 150,000 | $1.19 | $178.5K | 150.0K | Form 4 ↗ |
Aminov Erez Chief Executive Officer | Dec 9, 2024 | Award | 2,000,000 | $1.19 | $2.38M | 2.00M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
MIRA Pharmaceuticals, Inc. (MIRA) is primarily owned by institutional investors, who hold approximately 3.3% of total shares outstanding. Company insiders own approximately 36.07%, while retail and public investors account for the remaining 60.61%.
The largest institutional shareholder of MIRA Pharmaceuticals, Inc. is CROSS STAFF INVESTMENTS INC, holding approximately 359,401 shares — equal to 2.12% of outstanding shares — as of September 30, 2025.
A total of 29 institutional investors currently hold MIRA stock, with a combined institutional value of approximately $1,892,542 as of the most recent 13F filing period.
Frequently asked questions
MIRA ownershipMIRA Pharmaceuticals, Inc. (MIRA) is primarily owned by institutional investors, who hold approximately 3.3% of shares. The largest shareholder is CROSS STAFF INVESTMENTS INC with a 2.12% stake. Company insiders hold 36.07%. Data sourced from SEC Form 13F as of September 30, 2025.